CAR-T is one of the methods of adoptive cell transfer therapy (ACT); its main principle is to isolate T cells from patients, use genetic engineering technology to insert a chimeric antigen receptor (CAR) into the T cells that can recognize tumor cells and activate the T cells at the same time, and then infuse the expanded CAR-T cells back into the patients and attack the target cells expressing the relevant antigens without relying on the major histocompatibility complex (MHC) (4). This evidence concerns the gene HLA-C and neoplasm.